A Novel Peptide-Based Probe 99m Tc-PEG 6 -RD-PDP2 for the Molecular Imaging of Tumor PD-L2 Expression

Qi Luo,Yunwei Zhang,Zihua Wang,Yining Sun,Linqing Shi,Yue Yu,Jiyun Shi,Zhiyuan Hu,Fan Wang

DOI: https://doi.org/10.1016/j.cclet.2022.02.068

2022-01-01

Abstract:Tumor-related PD-L2 expression is associated with the clinical efficacy of PD-1/PD-L1 blockade therapy.PD-L2-specific imaging can help selecting patients for appropriate immunotherapy. In this study, a PD-L2-targeting peptide（PDP2） was screened by the one-bead one-compound combinatorial library approach.Using the retro-inverso D-peptide of PDP2（RD-PDP2） and PEGylation strategies, we developed a novel Tc-99m-labeled PD-L2-targeting peptide as a SPECT tracer( 99m Tc-PEG 6 -RD-PDP2) for imaging of tumor PD-L2 expression. The radiolabeling yield of 99m Tc-PEG 6 -RD-PDP2 was greater than 95% by the standard HYNIC/tricine/TPPTS labeling procedure. 99m Tc-PEG 6 -RD-PDP2 displayed high PD-L2-binding specificity both in vitro and in vivo. SPECT/CT imaging with 99m Tc-PEG 6 -RD-PDP2 showed that the A549-PD-L2tumors were clearly visualized, whereas the signals in PD-L2-negative A549 tumors were much lower.In vivo blocking study suggested that the tumor uptake of 99m Tc-PEG 6 -RD-PDP2 was PD-L2 specifically mediated. 99m Tc-PEG 6 -RD-PDP2 is a promising SPECT probe for the non-invasive imaging of tumor PD-L2expression and has a great potential in guiding the anti-PD-1 or anti-PD-L1 immunotherapy of cancer.